We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 30, 2021

Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Cancer 2021 Apr 15;[EPub Ahead of Print], N Fazio, C Carnaghi, R Buzzoni, JW Valle, F Herbst, A Ridolfi, J Strosberg, MH Kulke, ME Pavel, JC Yao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading